109 related articles for article (PubMed ID: 9029021)
21. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Budman DR; Petroni GR; Johnson JL; Cooper MR; Schlossman DM; Barcos M; Peterson BA
J Clin Oncol; 1997 Oct; 15(10):3275-9. PubMed ID: 9336365
[TBL] [Abstract][Full Text] [Related]
22. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
24. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
[TBL] [Abstract][Full Text] [Related]
25. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
26. Infusional vinorelbine in relapsed or refractory lymphomas.
Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
28. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Pro B; Fayad L; McLaughlin P; Romaguera J; Hagemeister FB; Rodriguez MA; Goy A; Loyer E; Younes A
Leuk Lymphoma; 2006 Mar; 47(3):481-5. PubMed ID: 16396772
[TBL] [Abstract][Full Text] [Related]
29. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Younes A; Ayoub JP; Hagemeister FB; McLaughlin P; Sarris A; Rodriguez MA; Swan F; Romaguera JE; Martin J; Cabanillas F
J Clin Oncol; 1996 Feb; 14(2):543-8. PubMed ID: 8636769
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
32. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
Br J Haematol; 2001 Dec; 115(4):786-92. PubMed ID: 11843810
[TBL] [Abstract][Full Text] [Related]
33. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel-based treatment of lymphoma.
Younes A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
[TBL] [Abstract][Full Text] [Related]
35. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
36. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
38. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Miller TP; Chase EM; Dorr R; Dalton WS; Lam KS; Salmon SE
Anticancer Drugs; 1998 Feb; 9(2):135-40. PubMed ID: 9510499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]